Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Fujian Haixi Pharmaceuticals Co FCF Yield %?
Fujian Haixi Pharmaceuticals CoHKSE:02637 +3.28%23 FCF Yield % is 0.79 as of Aug. 16, 2026, which is 23% below its 10-year median of 1.02. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 51.65% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Fujian Haixi Pharmaceuticals Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Fujian Haixi Pharmaceuticals Co FCF Yield % Related Terms
Fujian Haixi Pharmaceuticals Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co FCF Yield % Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
FCF Yield %
0.00
0.00
0.00
1.19
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
FCF Yield %
0.00
0.00
0.00
1.19
HKSE:02637 vs ZTS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a FCF Yield % of 0.79 as of Aug. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is 23% below median its historical median of 1.02. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #485 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 48.4%.
Is Fujian Haixi Pharmaceuticals Co's FCF Yield % too high?
Fujian Haixi Pharmaceuticals Co's current FCF Yield % of 0.79 is 23% below median its 10-year median of 1.02. The Drug Manufacturers industry median FCF Yield % is 0.64. Fujian Haixi Pharmaceuticals Co's value of 0.79 is 23.4% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #485 out of 1003 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #485 out of 1003 companies for FCF Yield %. This puts Fujian Haixi Pharmaceuticals Co in the upper half of its industry. The industry median FCF Yield % is 0.64. Fujian Haixi Pharmaceuticals Co's value of 0.79 is 23.4% above this benchmark. While the company's 10-year median is 1.02 vs. the industry median of 0.64, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.64, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current FCF Yield % of 0.79 is 23.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current FCF Yield % is 0.79, which is 23% below median its own 10-year median of 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current FCF Yield % of 0.79. The current FCF Yield % is 0.79, which is 23% below median its 10-year median of 1.02 and 23.4% above the Drug Manufacturers industry median of 0.64. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current FCF Yield % is 0.79 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
